Profile data is unavailable for this security.
About the company
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
- Revenue in JPY (TTM)8.12m
- Net income in JPY-1.07bn
- Incorporated2015
- Employees28.00
- LocationNoile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
- Phone+81 358437819
- Websitehttps://www.noile-immune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Metabolome Technologies Inc | 1.38bn | 246.02m | 3.58bn | 58.00 | 14.52 | 1.97 | 10.24 | 2.58 | 41.59 | 41.59 | 234.08 | 306.43 | 0.6291 | 8.87 | 7.76 | 23,872,380.00 | 11.18 | 8.49 | 14.00 | 10.80 | 65.13 | 69.25 | 17.77 | 13.21 | 3.73 | 33.22 | 0.1088 | 18.31 | 3.57 | -- | -14.88 | -- | -- | -- |
| Cyfuse Biomedical KK | 57.69m | -718.81m | 3.68bn | 21.00 | -- | 1.35 | -- | 63.72 | -89.81 | -89.81 | 7.24 | 335.21 | 0.0147 | 0.5261 | 40.19 | 2,747,238.00 | -18.36 | -- | -21.62 | -- | 55.40 | -- | -1,245.95 | -- | 5.52 | -91.45 | 0.2268 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| D.Western Therapeutics Institute Inc | 464.18m | -1.09bn | 4.25bn | 21.00 | -- | 4.34 | -- | 9.16 | -33.74 | -33.74 | 14.43 | 25.80 | 0.19 | 0.3314 | 4.10 | 22,103,620.00 | -44.77 | -13.06 | -47.81 | -14.36 | 91.27 | 94.29 | -235.62 | -72.51 | 18.24 | -- | 0.5644 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| BrightPath Biotherapeutics Co Ltd | 84.00k | -1.15bn | 4.26bn | 24.00 | -- | 3.39 | -- | 50,768.63 | -16.73 | -16.73 | 0.0012 | 14.73 | 0.00006 | -- | 2.80 | 3,500.00 | -80.63 | -51.56 | -97.29 | -54.32 | 75.00 | 68.63 | -1,372,495.00 | -22,321.82 | -- | -- | 0.2085 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
| FunPep Co Ltd | 530.00k | -727.29m | 4.41bn | 15.00 | -- | 1.65 | -- | 8,316.22 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kidswell Bio Corp | 3.60bn | -883.62m | 4.63bn | 42.00 | -- | 5.41 | -- | 1.29 | -22.78 | -22.78 | 92.26 | 21.08 | 0.9182 | 2.73 | 6.63 | 85,697,070.00 | -22.54 | -57.41 | -35.96 | -81.13 | 36.17 | 55.20 | -24.55 | -123.52 | 1.64 | -17.95 | 0.7132 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| DNA Chip Research Inc | 766.32m | -118.13m | 4.73bn | 37.00 | -- | 6.74 | -- | 6.17 | -18.29 | -18.29 | 116.80 | 103.64 | 0.9159 | 8.50 | 7.86 | 20,711,350.00 | -14.12 | -23.49 | -17.74 | -26.70 | 38.52 | 14.28 | -15.41 | -54.10 | 2.78 | -641.51 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Carna Biosciences, Inc. | 1.40bn | -1.51bn | 5.52bn | 67.00 | -- | 1.96 | -- | 3.94 | -85.98 | -85.98 | 80.34 | 147.09 | 0.391 | 1.19 | 13.59 | 20,922,580.00 | -42.15 | -14.45 | -45.45 | -16.95 | 87.53 | 90.59 | -107.80 | -35.42 | 11.11 | -- | 0.0215 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Veritas In Silico Inc | 246.24m | -148.31m | 5.85bn | 15.00 | -- | 2.54 | -- | 23.76 | -23.92 | -23.92 | 38.93 | 354.61 | 0.1227 | -- | -- | 16,415,930.00 | -7.39 | -- | -7.65 | -- | -- | -- | -60.23 | -- | 67.03 | -- | -- | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| Kringle Pharma Inc | 80.04m | -756.45m | 6.00bn | 13.00 | -- | 2.85 | -- | 74.97 | -118.21 | -118.21 | 12.71 | 309.55 | 0.0298 | -- | 1.15 | -- | -28.14 | -19.17 | -30.03 | -20.40 | -- | -- | -945.12 | -181.86 | 19.20 | -- | -- | -- | 15.58 | -- | 11.44 | -- | -- | -- |
| Chiome Bioscience Inc | 581.07m | -1.22bn | 6.24bn | 51.00 | -- | 5.04 | -- | 10.75 | -22.07 | -22.07 | 10.53 | 19.85 | 0.3371 | 5.16 | 8.01 | 11,393,550.00 | -70.61 | -50.50 | -95.97 | -57.38 | 53.55 | 57.53 | -209.45 | -224.74 | 3.57 | -894.37 | 0.1995 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
| Noile-Immune Biotech Inc | 8.12m | -1.07bn | 7.01bn | 28.00 | -- | 1.43 | -- | 864.12 | -24.64 | -24.64 | 0.1875 | 113.23 | 0.0015 | 0.0229 | 0.0283 | 289,928.60 | -19.15 | -- | -19.61 | -- | 95.58 | -- | -13,139.53 | -- | 79.60 | -- | -- | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| OncoTherapy Science, Inc. | 478.75m | -1.12bn | 8.42bn | 54.00 | -- | 8.42 | -- | 17.59 | -4.86 | -4.86 | 2.04 | 3.68 | 0.3526 | 4.34 | 9.77 | 8,865,722.00 | -82.71 | -55.67 | -106.53 | -63.82 | -32.12 | -1.49 | -234.61 | -247.47 | 3.11 | -- | 0.0731 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| TMS Co Ltd | 0.00 | -1.10bn | 8.47bn | 14.00 | -- | 2.83 | -- | -- | -28.37 | -28.37 | 0.00 | 74.10 | 0.00 | -- | -- | 0.00 | -33.57 | -- | -34.42 | -- | -- | -- | -- | -- | 31.13 | -- | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
| Linical Co Ltd | 11.67bn | -121.16m | 8.51bn | 662.00 | -- | 1.05 | 20.71 | 0.7293 | -5.36 | -5.36 | 516.67 | 326.90 | 0.6575 | -- | 3.74 | 17,628,030.00 | -0.6826 | 4.01 | -1.18 | 6.33 | 26.63 | 30.99 | -1.04 | 5.48 | -- | 2.65 | 0.2588 | 50.81 | -1.67 | 1.70 | -66.32 | -9.86 | -10.18 | 4.56 |
| Modalis Therapeutics Corp | 0.00 | -1.87bn | 9.09bn | 37.00 | -- | 2.95 | -- | -- | -52.79 | -52.79 | 0.00 | 44.35 | 0.00 | -- | -- | 0.00 | -74.95 | -29.19 | -78.46 | -30.02 | -- | -- | -- | -597.35 | 43.87 | -87.46 | 0.0771 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
Data as of Nov 22 2024. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY
0.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 28 Jun 2023 | 130.10k | 0.30% |
| Simplex Asset Management Co., Ltd.as of 07 Nov 2024 | 51.70k | 0.12% |
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
